Jump to content

Wikipedia:WikiProject Chemicals/Chembox validation/VerifiedDataSandbox and Halazepam: Difference between pages

(Difference between pages)
Page 1
Page 2
Content deleted Content added
Saving copy of the {{drugbox}} taken from revid 461607775 of page Halazepam for the Chem/Drugbox validation project (updated: 'DrugBank').
 
 
Line 1: Line 1:
{{Short description|Chemical compound}}
{{ambox | text = This page contains a copy of the infobox ({{tl|drugbox}}) taken from revid [{{fullurl:Halazepam|oldid=461607775}} 461607775] of page [[Halazepam]] with values updated to verified values.}}
{{Drugbox
{{Drugbox
| Watchedfields = changed
| verifiedrevid = 418945949
| verifiedrevid = 461743655
| IUPAC_name = 7-chloro- 5-phenyl- 1-(2,2,2-trifluoroethyl) -1,3-dihydro- 2''H''-1,4-benzodiazepin- 2-one
| IUPAC_name = 7-chloro-5-phenyl-1-(2,2,2-trifluoroethyl)-3''H''-1,4-benzodiazepin-2-one
| image = Halazepam.svg
| image = Halazepam.svg
| width = 220
| width = 170
| image2 = Halazepam3d.png
| image2 = Halazepam3d.png
| width2 = 150


<!--Clinical data-->
<!--Clinical data-->
| tradename =
| tradename =
| Drugs.com = {{drugs.com|CONS|halazepam}}
| Drugs.com = {{drugs.com|CONS|halazepam}}
| MedlinePlus = a684001
| MedlinePlus = a684001
| pregnancy_category = ?
| pregnancy_category = ?
| legal_BR = B1
| legal_status = [[Schedule IV controlled substance|Schedule IV]] (US)
| legal_BR_comment = <ref>{{Cite web |author=Anvisa |author-link=Brazilian Health Regulatory Agency |date=2023-03-31 |title=RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial |trans-title=Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control|url=https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 |url-status=live |archive-url=https://web.archive.org/web/20230803143925/https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 |archive-date=2023-08-03 |access-date=2023-08-16 |publisher=[[Diário Oficial da União]] |language=pt-BR |publication-date=2023-04-04}}</ref>
| legal_CA = Schedule IV
| legal_DE = Rx-only/Anlage III
| legal_US = Schedule IV
| routes_of_administration = Oral
| routes_of_administration = Oral


<!--Pharmacokinetic data-->
<!--Pharmacokinetic data-->
| bioavailability = ?
| bioavailability =
| metabolism = [[Liver|Hepatic]]
| metabolism = [[Liver|Hepatic]]
| elimination_half-life = ?
| elimination_half-life = 14 hours (halazepam), 50–100 hours (metabolites).
| excretion = [[Kidney|Renal]]
| excretion = [[Kidney|Renal]]


<!--Identifiers-->
<!--Identifiers-->
| IUPHAR_ligand = 7195
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 23092-17-3
| CAS_number = 23092-17-3
Line 40: Line 46:


<!--Chemical data-->
<!--Chemical data-->
| C=17 | H=12 | Cl=1 | F=3 | N=2 | O=1
| C=17 | H=12 | Cl=1 | F=3 | N=2 | O=1
| smiles = FC(F)(CN1C(CN=C(C2=CC=CC=C2)C3=C1C=CC(Cl)=C3)=O)F
| molecular_weight = 352.7
| smiles = FC(F)(F)CN1C(=O)C/N=C(\c2cc(Cl)ccc12)c3ccccc3
| InChI = 1/C17H12ClF3N2O/c18-12-6-7-14-13(8-12)16(11-4-2-1-3-5-11)22-9-15(24)23(14)10-17(19,20)21/h1-8H,9-10H2
| InChIKey = WYCLKVQLVUQKNZ-UHFFFAOYAZ
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C17H12ClF3N2O/c18-12-6-7-14-13(8-12)16(11-4-2-1-3-5-11)22-9-15(24)23(14)10-17(19,20)21/h1-8H,9-10H2
| StdInChI = 1S/C17H12ClF3N2O/c18-12-6-7-14-13(8-12)16(11-4-2-1-3-5-11)22-9-15(24)23(14)10-17(19,20)21/h1-8H,9-10H2
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = WYCLKVQLVUQKNZ-UHFFFAOYSA-N
| StdInChIKey = WYCLKVQLVUQKNZ-UHFFFAOYSA-N
| synonyms = <small>9-chloro- 6-phenyl- 2-(2,2,2-trifluoroethyl)- 2,5-diazabicyclo[5.4.0] undeca- 5,8,10,12-tetraen -3-one</small>
| synonyms = <small>9-chloro-6-phenyl-2-(2,2,2-trifluoroethyl)-2,5-diazabicyclo[5.4.0]undeca-5,8,10,12-tetraen-3-one</small>
}}
}}

'''Halazepam''' is a [[benzodiazepine]] derivative that was marketed under the brand names '''Paxipam''' in the United States,<ref name=DrugsH /> '''Alapryl''' in Spain,<ref name=DrugsA>{{cite web|title=Alapryl|url=https://www.drugs.com/international/alapryl.html|publisher=Drugs.com|access-date=December 11, 2014}}</ref> and '''Pacinone''' in Portugal.<ref name=DrugsP>{{cite web|title=Pacinone|url=https://www.drugs.com/international/pacinone.html|publisher=Drugs.com|access-date=December 11, 2014}}</ref>

==Medical uses==
Halazepam was used for the treatment of [[anxiety]].<ref name=DrugsH />

==Adverse effects==
Adverse effects include drowsiness, confusion, dizziness, and sedation. Gastrointestinal side effects have also been reported including dry mouth and nausea.<ref name=DrugsH />

==Pharmacokinetics and pharmacodynamics==
Pharmacokinetics and pharmacodynamics were listed in ''Current Psychotherapeutic Drugs'' published on June 15, 1998 as follows:<ref>{{cite book| veditors = Quitkin FM, etal | vauthors = Sellers EM | chapter = Antianxiety agents: benzodiazepine derivatives |title = Current Psychotherapeutic Drugs |date=1998|publisher=American Psychiatric Press|location=Washington|isbn=978-0-88048-994-2 |page=166|edition=2nd}}</ref>

{| class="wikitable"
|-
| Onset of action || Intermediate to slow
|-
| Plasma half life || 14 hr for parent drug and 30-100 hr for its metabolite
|-
| Peak plasma levels || 1-3 hr for parent drug and 3-6 hf for its metabolite
|-
| Metabolism || Metabolized into desmethyldiazepam and 3-hydroxyhalazepam (in the liver)
|-
| Excretion || Excreted through kidneys
|-
| Protein binding|| 98% bound to plasma protein
|}

==Regulatory Information==
Halazepam is classified as a [[Controlled Substances Act#Schedule IV controlled substances|schedule 4]] [[controlled substance]] with a corresponding code 2762 by the [[Drug Enforcement Administration]] (DEA).<ref name=DEA>{{cite web|title=SCHEDULES OF CONTROLLED SUBSTANCES|url=http://www.gpo.gov/fdsys/pkg/CFR-2012-title21-vol9/xml/CFR-2012-title21-vol9-part1308.xml|publisher=Code of Federal Regulations|access-date=December 12, 2014|pages=§ 1308.14 Schedule IV|date=2012-04-01}}</ref>

==Commercial production==
Halazepam was invented by Schlesinger Walter in the U.S. It was marketed as an anti-anxiety agent in 1981. However, Halazepam is not commercially available in the United States because it was withdrawn by its manufacturer for poor sales.<ref name=DrugsH>{{cite web|title=halazepam|url=https://www.drugs.com/mtm/halazepam.html|publisher=Drugs.com|access-date=December 11, 2014}}</ref>

==See also==
*[[Benzodiazepine]]s
*[[Nordazepam]]
*[[Diazepam]]
*[[Chlordiazepoxide]]
*[[Quazepam]], [[fletazepam]], [[triflubazam]] — benzodiazepines with [[trifluoromethyl group]] attached

==References==
{{Reflist}}

==External links==
* [http://www.inchem.org/documents/pims/pharm/pim160.htm Inchem - Halazepam]

{{Benzodiazepines}}
{{Anxiolytics}}
{{GABAAR PAMs}}

[[Category:Withdrawn drugs]]
[[Category:Benzodiazepines]]
[[Category:Chloroarenes]]
[[Category:Lactams]]
[[Category:Trifluoromethyl compounds]]


{{sedative-stub}}